Apramycin is an aminoglycoside antibiotic for veterinary use that is used to treat infections in animals. Apramycin is an aminoglycoside antibiotic and has a bactericidal action against many gram-negative bacteria.
- Mechanism
- Curator reviewed
Apramycin stands out among aminoglycosides for its mechanism of action which is based on blocking translocation and its ability to bind also to the eukaryotic decoding site despite differences in key residues required for apramycin recognition by the bacterial target. The drug binds in the deep groove of the RNA which forms a continuously stacked helix comprising non-canonical C.A and G.A base pairs and a bulged-out adenine. The binding mode of apramycin at the human decoding-site RNA is distinct from aminoglycoside recognition of the bacterial target, suggesting a molecular basis for the actions of apramycin in eukaryotes and bacteria.
- Primary indication
- For the treatment of bacterial infections in animals.Curator reviewed
- Formula / weight
- C21H41N5O11 · 539.5771 g/mol (avg)
- Also known as
- Nebramycin II
- Code names
- EL-857
Resolves to
XZNUGFQTQHRASN-XQENGBIVSA-NSMILESCN[C@H]1[C@@H](O)[C@H]2O[C@H](O[C@@H]3[C@@H](N)C[C@@H](N)[C@H](O)[C@H]3O)[C@H](N)C[C@@H]2O[C@@H]1O[C@H]1O[C@H](CO)[C@@H](N)[C@H](O)[C@H]1OWhat you can answer from here — as of September 13, 2026
Which companies are running trials of Apramycin, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account